Results 291 to 300 of about 357,544 (339)

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE. [PDF]

ESMO Open
Fayette J, Cropet C, Toullec C, Burgy M, Bruyas A, Sire C, Lagrange A, Clatot F, Vinches M, Iacob M, Martin L, Kaminsky MC, Vansteene D, Salas S, Champagnac A, Saintigny P, Gautier J, Pérol D, Bourhis J.   +18 more
europepmc   +1 more source

From Innovation to Validation: Strengthening Interventional Radiology Through Data

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Kaiwen Cabbabe, Gerard S. Goh, Charles Li, Matthew Lukies   +3 more
wiley   +1 more source

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Lancet, The, 2023
Summary Background Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for ...
Andrew Dean
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Journal of Clinical Oncology, 2023
PURPOSE To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. PATIENTS AND METHODS In a phase II trial, 99 patients were randomly assigned to bevacizumab 7.
David H. Johnson, L. Fehrenbacher, W. Novotny, R. Herbst, J. Nemunaitis, D. Jablons, C. Langer, R. Devore, J. Gaudreault, L. Damico, E. Holmgren, F. Kabbinavar   +11 more
semanticscholar   +1 more source

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Lancet, The, 2018
BACKGROUND Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastro-oesophageal junction cancer that ...
Kohei Shitara, Mustafa ÖzgÜroglu, Maria Di Bartolomeo   +2 more
exaly   +2 more sources

Paclitaxel

Reactions Weekly, 2019
Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and
Fulwah Yahya, Alqahtani, Fadilah Sfouq, Aleanizy, Eram, El Tahir, Hamad M, Alkahtani, Bushra T, AlQuadeib   +4 more
openaire   +3 more sources

Paclitaxel (Taxol)

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1994
Paclitaxel is a novel antineoplastic that effects cytotoxicity by promoting intracellular tubulin polymerization and stabilizes abnormal microtubule structures against depolymerization. Although its clinical development had been hampered by misconceptions about its pharmacology, its scarcity, difficulties extracting it from its natural source ...
D R, Kohler, B R, Goldspiel
openaire   +2 more sources

Paclitaxel resistance related to nuclear envelope structural sturdiness.

Drug resistance updates, 2022
Taxanes (Taxol/paclitaxel, Docetaxel/taxotere) are a key group of successful drugs commonly used in chemotherapy to treat several major malignant tumors also as a front-line agent in combination with carboplatin/cisplatin, as well as a second line drug ...
Elizabeth R. Smith, Jing-Quan Wang, Dong-Hua Yang, Xiang-Xi Xu   +3 more
semanticscholar   +1 more source

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet Oncology, 2019
BACKGROUND Immunotherapy in combination with chemotherapy has shown promising efficacy across many different tumour types. We report the prespecified second interim overall survival analysis of the phase 3 IMpassion130 study assessing the efficacy and ...
P. Schmid, H. Rugo, S. Adams, A. Schneeweiss, C. Barrios, H. Iwata, V. Diéras, V. Henschel, L. Molinero, S. Chui, V. Maiya, A. Husain, E. Winer, S. Loi, L. Emens   +14 more
semanticscholar   +1 more source